Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 45,506

Document Document Title
WO/2014/042238
The invention provides a novel sulfonamide compound useful as a drug having a TRPM8-blocking effect. Specifically, the invention provides a sulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I...  
WO/2014/042176
Provided are an industrially useful method for producing a fused-heterocyclic derivative or salt thereof which is useful as a preventive agent, therapeutic agent, reproductive adjustment agent, contraceptive, ovulation-inducing agent, or...  
WO/2014/041175
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q1, Q2 have the following meanings: X is C-R3 or...  
WO/2014/043368
Disclosed are methods for enhancing learning and/or memory, enhancing memory acquisition, memory retention and recall by inducing a higher long-term potentiation in hippocampal neuronal synapsis in individuals. The methods include admini...  
WO/2014/043068
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and...  
WO/2014/039501
Bolaamphiphilic compounds are provided according to formula (I): where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into anim...  
WO/2014/037532
The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-lH-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropo xy)benzylamine to improve or augment the effect of an acetylcho...  
WO/2014/036595
The present disclosure relates to quinoline compounds of formula I, compositions comprising them and methods and uses for the treatment of central nervous system disorders, such as mood disorders (eg. depression), anxiety disorders, and ...  
WO/2014/039411
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may ...  
WO/2014/037412
The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising a...  
WO/2014/039908
Provided are methods and compositions for inducing cells of the inner ear (for example, cochlear and utricular hair cells) to reenter to cell cycle and to proliferate. More particularly, the invention relates to the use of agents that in...  
WO/2014/038878
The present invention relates to a composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk as an active ingredient, and the composition has an outstanding pharmacological eff...  
WO/2014/038623
Provided is a therapeutic agent for diseases associated with central nervous system (CNS) and/or peripheral nervous system (PNS) cholinergicity, diseases associated with smooth muscle contraction, endocrine diseases, diseases associated ...  
WO/2014/039504
Bolaamphiphilic compounds are provided according to formula I where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering biologically active drug...  
WO/2014/037881
The present invention pertains to the field of genomics and nanotechnology, specifically to the in vivo gene expression technologies and their application in gene therapy. It consists of the performance of the NTS-polyplex nanocomplex, w...  
WO/2014/039434
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising t...  
WO/2014/040076
The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α.  
WO/2014/039138
The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acy...  
WO/2014/035860
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β- secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in...  
WO/2014/034756
The present invention relates to the provision of a pharmaceutical composition for use in the treatment of status epilepticus or a method for treating status epilepticus. The present invention provides a pharmaceutical composition for us...  
WO/2014/034719
A compound represented by general formula (1), a salt of the compound, or a solvate of the compound or the salt, which can inhibit TLR3, 7 and/or 9 and has an excellent prophylactic and/or therapeutic effect on autoimmune diseases, infla...  
WO/2014/034898
The main purpose of the invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include a pyridine derivative represented by general formula [1], and a pharmaceutically...  
WO/2014/032187
The invention provides compounds of Formula (I) for inhibiting gh cosidases, prodrugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides method of treating...  
WO/2014/033530
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein G, R2-R5, and (a) are defined as set forth in the specification. The invention is also directed to use...  
WO/2014/035707
The present invention provides compounds and composition comprising analogs of deprenyl and their use in the inhibition of nuclear GAPDH-Siahl binding and the activation of p300 and MEF2. Also provided herein are methods of prevention an...  
WO/2014/032732
The invention relates to novel halogenated benzoxazines, to methods for the production thereof, use thereof for the diagnosis of diseases and to the use thereof for producing medicaments for the diagnosis of diseases, preferably dementia...  
WO/2014/032801
The invention relates to pyrrole carboxamides bearing a fluoromethyl- moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or...  
WO/2014/034890
A hypnotic/sedative agent comprising methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2- a][1,4]benzodiazepin-4-yl]propanoate or a salt thereof is administered to a vein of a patient by a two-step administration method as dis...  
WO/2014/032185
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...  
WO/2014/032184
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...  
WO/2014/032188
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...  
WO/2014/034939
The purpose of the present invention is to provide a rivastigmine-containing adhesive skin patch which has excellent skin permeability of rivastigmine contained therein and has excellent adhesion performance. The present invention provid...  
WO/2014/036379  
WO/2014/033074
The present disclosure relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.  
WO/2014/034929
The present invention addresses the problem of providing a hydromorphone hydrochloride- or oxycodone hydrochloride hydrate-containing orally-administered sustained-release pharmaceutical composition, which exhibits a reliable main pharma...  
WO/2014/035355
The present invention is related to pharmaceutical compositions comprising idebenone and memantine in combination which are used in the treatment of cerebral arteriosclerosis, symptoms following stroke and cerebral hemorrhage, age-associ...  
WO/2014/036427
Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptav...  
WO/2014/031792
Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepti...  
WO/2014/029924
The present invention relates to novel nutritional and nutraceutical therapeutic uses of lactoferrin in psychiatric or non-degenerative neurological diseases.  
WO/2014/031584
The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of ...  
WO/2014/030716
Provided is a pyrazolopyrimidine compound represented by formula (I) having an HIF-PHD inhibitory effect, or a pharmaceutically acceptable salt thereof. [In the formula, AA indicates an optionally substituted 7-hydroxypyrazolo[4,3-d]pyri...  
WO/2014/030170
The present invention relates to novel acrylamide compounds of formula (I), and their pharmaceutically acceptable salts and process of their preparation. (The chemical formula should be inserted here.) The compounds of formula (I) are us...  
WO/2014/031883
There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparti...  
WO/2014/029732
The present invention relates to the use of novel pyrrolo[2,3- b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory dise...  
WO/2014/031656
Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of ol...  
WO/2014/031403
A method of treating an animal suffering from a painful condition or disease comprising administering to the animal an effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein, the animal is live...  
WO/2014/031844
Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.  
WO/2014/031901
Methods of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from: (i) monomethyl fumarate, (ii) a prodrug of monomethyl fumarate, an...  
WO/2014/031694
The disclosure provides antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes). The antibodies may be used to treat tauopa...  
WO/2014/031894
Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.  

Matches 101 - 150 out of 45,506